Acasă › Cancer de sân › Missouri › Kansas City
Studii clinice pentru Cancer de sân în Kansas City, MO
34 studii pentru Cancer de sân caută participanți în și în jurul orașului Kansas City (în aproximativ 50 km). Deschideți un studiu pentru a vedea criteriile de eligibilitate și cum să contactați echipa de cercetare.
Text oficial al studiului (în engleză)
The Vanguard Study: Testing a New Way to Screen for Cancer
În curs de recrutareVoluntari sănătoși bineveniți
- Saint Luke's Hospital of Kansas City, Kansas City
Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
În curs de recrutareFaza 3
- University of Kansas Cancer Center, Westwood · La 5 mi distanță
Phase IIIb Study of Ribociclib + ET in Early Breast Cancer
În curs de recrutareFaza 3
- HCA Midwest Division, Kansas City
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
În curs de recrutareStudiu observaționalVoluntari sănătoși bineveniți
- Kansas City Veterans Affairs Medical Center, Kansas City
A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer
În curs de recrutareFaza 2
- Saint Luke's Cancer Institute, Kansas City
Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
În curs de recrutareFaza 1
- St. Lukes Hospital of Kansas City, Kansas City
A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)
În curs de recrutareFaza 3
- Saint Luke's Cancer Institute ( Site 0027), Kansas City
The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study
În curs de recrutareFaza 3
- The University of Kansas Cancer Center, Westwood · La 5 mi distanță
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
În curs de recrutareFaza 3
- Saint Luke's Cancer Institute ( Site 0059), Kansas City
Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer
În curs de recrutareFaza 3
- Clinical Trial Site, Kansas City
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
În curs de recrutareFaza 3
- Saint Luke's Cancer Institute, Kansas City
A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast Cancer
În curs de recrutareFaza 1/2
- Saint Luke's Hospital of Kansas City, Kansas City
ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer
În curs de recrutareFaza 3
- Saint Luke's Hospital of Kansas City, Kansas City
A Phase 1/1b Study of IAM1363 in HER2 Cancers
În curs de recrutareFaza 1
- Saint Luke's Cancer Institute, Kansas City
To Study the Effect of Inavolisib in Combination With Fulvestrant in Participants With Breast Cancer
În curs de recrutareFaza 2
- HCA Midwest Division, Kansas City
A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
În curs de recrutareFaza 3
- HCA Midwest Health, Kansas City
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
În curs de recrutareFaza 3
- University Health Truman Medical Center, Kansas City
- University of Kansas Cancer Center - Briarcliff, Kansas City
- University of Kansas Cancer Center - North, Kansas City
- și încă 1
Triple Negative Breast Cancer and Germline Hereditary Breast and Ovarian Cancer Mutation Carrier Registry
În curs de recrutareStudiu observaționalVoluntari sănătoși bineveniți
- Universtiy Health, Kansas City
- KCCC South, Kansas City
- Research Medical Center, Kansas City
- și încă 2
Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM Trial
În curs de recrutareFaza 3
- University of Kansas Cancer Center - North, Kansas City
A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
În curs de recrutareFaza 2/3
- Saint Luke's Cancer Institute, Kansas City
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
În curs de recrutareFaza 1/2
- University of Kansas Medical Center (KUMC), Westwood · La 5 mi distanță
HER2-positive Breast Cancer Registry
În curs de recrutareStudiu observațional
- The University of Kansas Cancer Center, Westwood · La 5 mi distanță
First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
În curs de recrutareFaza 1/2
- Saint Luke's Cancer Institute, Kansas City
Integrated Cancer Repository for Cancer Research
În curs de recrutareStudiu observaționalVoluntari sănătoși bineveniți
- Saint Luke's Cancer Institute, East, Kansas City
- Saint Luke's Cancer Institute, Kansas City
- Saint Luke's Cancer Institute, Kansas City North, Kansas City
- și încă 1
Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation
În curs de recrutareFaza 3
- Saint Luke's Cancer Institute, Kansas City
Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)
În curs de recrutareFaza 3
- Saint Luke's Cancer Institute, Kansas City
- The University of Kansas Cancer Center, Westwood · La 5 mi distanță
Trial of Neoadjuvant THP vs TCHP for HER2-Amplified/Positive Breast Cancer
În curs de recrutareFaza 2
- The University of Kansas Cancer Center - North, Kansas City
- KUCC - Briarcliff, Westwood · La 5 mi distanță
- KUCC - Olathe, Westwood · La 5 mi distanță
A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
În curs de recrutareFaza 3
- Saint Luke's Hospital of Kansas City, Kansas City
De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)
În curs de recrutareFaza 3
- University of Kansas Cancer Center - Briarcliff, Kansas City
- University of Kansas Cancer Center - North, Kansas City
- University of Kansas Cancer Center at North Kansas City Hospital, North Kansas City · La 2 mi distanță
- și încă 1
Zunsemetinib in Combination With Capecitabine in Patients With Hormone Receptor-Positive and HER2-Negative Metastatic Breast Cancer With Bone Metastasis
În curs de recrutareFaza 1/2
- The University of Kansas Cancer Center, Westwood · La 5 mi distanță
Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
În curs de recrutareStudiu observațional
- University Health Truman Medical Center, Kansas City
- University of Kansas Cancer Center - Briarcliff, Kansas City
- University of Kansas Cancer Center - North, Kansas City
- și încă 1
EXActDNA-003 / NSABP B-64: Study of Molecular Residual Disease Detection in Breast Cancer (MRD)
În curs de recrutareStudiu observațional
- Saint Luke's Hospital of Kansas City, Kansas City
- University of Kansas Cancer Center, Westwood · La 5 mi distanță
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
În curs de recrutareStudiu observațional
- Massive Bio SYNERGY-AI site, Kansas City
S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity
În curs de recrutareFaza 3
- Truman Medical Centers, Kansas City
- University of Kansas Cancer Center - North, Kansas City
- University of Kansas Cancer Center at North Kansas City Hospital, North Kansas City · La 2 mi distanță
- și încă 1
Studii pentru Cancer de sân în alte orașe
- New York City, NY136 studii
- Houston, TX126 studii
- Boston, MA112 studii
- Nashville, TN81 studii
- Los Angeles, CA73 studii
- Edison, NJ68 studii
- St. Louis, MO64 studii
- Queens, NY64 studii
- Durham, NC64 studii
- Chicago, IL59 studii
- Philadelphia, PA56 studii
- Dallas, TX55 studii
Alte studii în Kansas City
- Cancer pulmonar cu celule non-pătrate31 studii
- Insuficiență cardiacă25 studii
- Cancer (toate tipurile)21 studii
- Cancer pulmonar19 studii
- Cancer colorectal16 studii
- Cancer metastatic15 studii
- Leucemie mieloasă acută15 studii
- Cancer de prostată14 studii
- Cancer ovarian11 studii
- Obezitate11 studii
- Diabet de tip 211 studii
- Boli cardiovasculare11 studii
Sursă: ClinicalTrials.gov, date preluate la 6 oct. 2026. Fiecare studiu are propriile criterii de eligibilitate; echipa de cercetare decide cine poate participa.